Published in:
Open Access
01-12-2020 | Melanoma | Research
Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma
Authors:
Runhua Feng, Yuling Wang, Vijaya Ramachandran, Qinhong Ma, Matthew M. May, Ming Li, Joe X. Zhou, Xiang Xu, Kejing Xu, Shenying Fang, Weiya Xia, Dawen Sui, Huey Liu, Xiaolian Gao, Victor Prieto, Stephen C. Blacklow, Mason Lu, Jeffrey E. Lee
Published in:
Journal of Experimental & Clinical Cancer Research
|
Issue 1/2020
Login to get access
Abstract
Background
MUC18 is a glycoprotein highly expressed on the surface of melanoma and other cancers which promotes tumor progression and metastasis. However, its mechanism of action and suitability as a therapeutic target are unknown.
Methods
A monoclonal antibody (mAb) (JM1-24-3) was generated from metastatic melanoma tumor live cell immunization, and high-throughput screening identified MUC18 as the target.
Results
Analysis of molecular interactions between MUC18 and JM1-24-3 revealed that the downstream signaling events depended on binding of the mAb to a conformational epitope on the extracellular domain of MUC18. JM1-24-3 inhibited melanoma cell proliferation, migration and invasion in vitro and reduced tumor growth and metastasis in vivo.
Conclusion
These results confirm that MUC18 is mechanistically important in melanoma growth and metastasis, suggest that the MUC18 epitope identified is a promising therapeutic target, and that the JM1-24-3 mAb may serve as the basis for a potential therapeutic agent.